The CVCT Forum is an annual, invite-only workshop that aims to cultivate a multi-stakeholder exchange to enhance clinical trials, streamline regulatory approval processes, and facilitate the ...

This crack team of former BioWare developers who helped craft " Mass Effect " is in full force here on "Exodus, " and we ...

The publication, titled “Prime Editing for p47-phox Chronic Granulomatous Disease,” reports initial data for two patients treated in the Phase 1/2 trial of PM359, which was designed to assess safety, ...

RMAT designation indicates that SENTI-202 has the potential to address unmet medical needs for patients with Relapsed/Refractory (R/R) Acute ...

Before heading back into the wasteland for “Fallout” season 2, here’s a quick look at the essential moments, locations, and ...

Bionano Genomics (NASDAQ: BNGO) participated in the Association for Molecular Pathology (AMP) Annual Meeting, held November 11-15, 2025 in Boston, MA. Key presentations at the conference highlighted ...

Harmony Biosciences Holdings, Inc. , today announced the presentation of initial open-label extension (OLE) data from the company's ongoing Phase 3 ARGUS trial investigating EPX-100 (clemizole ...

MEDSIR, a leading international company in oncology research, has announced the results of the PHERGuide study during the 2025 San Antonio Breast Cancer Symposium (SABCS). This research, presented as ...

AMCP Nexus 2025 explored innovative health care policies, oncology advancements, and the impact of new regulations on patient ...

Company invites individual and institutional investors, as well as advisors and analysts, to attend online at ...

Detailed price information for Telo Genomics Corp (TELO-X) from The Globe and Mail including charting and trades.

TuHURA Biosciences, Inc.  ("TuHURA"), a Phase 3 immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today announced that its research on the potential ...